MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION: Form 990, tax year 2021
View the entire original 990 at ProPublica ↗
- Organization
- MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION (EIN 31-1611837)
- Tax period
- 2021-07-01 to 2022-06-30
- Filed
- 2023-02-14
- IRS object ID
- 202310459349301411
- Schema version
- 2021v4.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2023-02-14T12:26:33-06:00 | ReturnTs |
| Tax Period End | 2022-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 101540102 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2021-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 311611837 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | MARC LUSTGARTEN PANCREATIC CANCER | BusinessNameLine1Txt |
| Business Name Line2 | FOUNDATION | BusinessNameLine2Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | MARC | BusinessNameControlTxt |
| Phone | 5167371550 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 415 CROSSWAYS PARK DRIVE D | AddressLine1Txt |
| City | WOODBURY | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 11797 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | LINDA TANTAWI | PersonNm |
| Person Title | CEO | PersonTitleTxt |
| Phone | 5167371550 | PhoneNum |
| Signature | 2023-02-13 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | LINDA | PersonFirstNm |
| Person Last | TANTAWI | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | DEVIN L DUNCAN | PreparerPersonNm |
| PTIN | P01249521 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2023-02-13 | PreparationDt |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 3 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2021 | TaxYr |
| Build TS | 2023-03-07 01:45:13Z | BuildTS |
Form 990 IRS990
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | LUSTGARTEN FOUNDATION | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | LINDA TANTAWI | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 415 CROSSWAYS PARK DRIVE D | AddressLine1Txt |
| City | WOODBURY | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 11797 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $176,264,716 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.LUSTGARTEN.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1998 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD.THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE. SINCE ITS INCEPTION, THE LUSTGARTEN FOUNDATION HAS DIRECTED MORE THAN $250 MILLION TO RESEARCH AND HAS ASSEMBLED THE BEST SCIENTIFIC MINDS WITH THE HOPE THAT ONE DAY, A CURE CAN BE FOUND. | ActivityOrMissionDesc |
| Voting Members Governing Body | 17 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 17 | VotingMembersIndependentCnt |
| Total Employee | 25 | TotalEmployeeCnt |
| Total Volunteers | 300 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $15,661,608 | PYContributionsGrantsAmt |
| CY Contributions Grants | $20,139,699 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $7,644,241 | PYInvestmentIncomeAmt |
| CY Investment Income | $10,583,001 | CYInvestmentIncomeAmt |
| PY Other Revenue | $1,161,984 | PYOtherRevenueAmt |
| CY Other Revenue | -$276,195 | CYOtherRevenueAmt |
| PY Total Revenue | $24,467,833 | PYTotalRevenueAmt |
| CY Total Revenue | $30,446,505 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $15,742,900 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $25,469,007 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $3,030,185 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $4,076,717 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $697,612 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $521,137 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $3,350,144 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $2,255,332 | PYOtherExpensesAmt |
| CY Other Expenses | $3,767,796 | CYOtherExpensesAmt |
| PY Total Expenses | $21,726,029 | PYTotalExpensesAmt |
| CY Total Expenses | $33,834,657 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $2,741,804 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$3,388,152 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $96,561,632 | TotalAssetsBOYAmt |
| Total Assets EOY | $78,505,397 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $3,614,475 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $8,473,764 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $92,947,157 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $70,031,633 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. SEE SCHEDULE O.THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $26,550,891 | ExpenseAmt |
| Grant | $25,469,007 | GrantAmt |
| Desc | RESEARCH PROGRAM: THE FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. TO MAKE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $25 MILLION TO RESEARCH DURING FY2022, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2022 TO $250 MILLION. SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $677,642 | ExpenseAmt |
| Desc | PUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $817,430 | ExpenseAmt |
| Desc | PROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE LABS PROGRAM SITES, AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFICMEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. SEE SCHEDULE O. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $28,045,963 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | 0 | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | 0 | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (1) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 19 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 25 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 17 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 17 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FAISAL JAWAID | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 5167371555 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 415 CROSSWAYS PARK DRIVE SUITE D | AddressLine1Txt |
| City | WOODBURY | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 11797 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (25 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| ANDREW LUSTGARTEN | |||||||||
| CHAIRMAN | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| CHARLES F DOLAN | |||||||||
| CHAIRMAN EMERITUS | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| ROBERT F VIZZA | |||||||||
| CHAIRMAN EMERITUS | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| JENNIE FORTUNOFF | |||||||||
| SECRETARY | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| PHILIP D'AMBROSIO | |||||||||
| TREASURER (AS OF 5/13/22) | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| WILLIAM BELL | |||||||||
| TREASURER/DIRECTOR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| JAMES L DOLAN | |||||||||
| VICE CHAIRMAN | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| ADAM SILVER | |||||||||
| VICE CHAIRMAN | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| SOMMER BAZURO PHD | |||||||||
| DIRECTOR (AS OF 2/9/22) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN H COBB | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JESSICA LUSTGARTEN COURTEMANCHE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| QUENTIN F DOLAN | |||||||||
| TRUSTEE | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KENNETH GOODMAN MD FACR | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| MARCIA LUSTGARTEN | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| SHEILA MAHONY | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| CHARLES R SCHUELER | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| WILLA SHALIT | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| LINDA TANTAWI | |||||||||
| CEO | 40.00 | 0.00 | Yes (X) | $385,092 | $0 | $52,597 | |||
| JOHANNA RICHMAN | |||||||||
| CFO | 40.00 | 0.00 | Yes (X) | $283,726 | $0 | $42,876 | |||
| KERRI KAPLAN | |||||||||
| PRESIDENT | 40.00 | 0.00 | Yes (X) | $331,122 | $0 | $34,257 | |||
| CATHERINE WEBER | |||||||||
| VP DEVELOPMENT OPS & CONSITUENT SVCS | 40.00 | 0.00 | $235,698 | $0 | $35,708 | Yes (X) | |||
| STEPHANIE ELSEA | |||||||||
| VP MARKETING & COMMUNICATIONS | 40.00 | 0.00 | $205,524 | $0 | $21,012 | Yes (X) | |||
| ANDREW RAKEMAN | |||||||||
| VP RESEARCH | 40.00 | 0.00 | $249,078 | $0 | $46,395 | Yes (X) | |||
| JASON RICE | |||||||||
| NAT DIR OF EVENTS (END 11/21/21) | 40.00 | 0.00 | $139,771 | $0 | $5,789 | Yes (X) | |||
| STEPHANIE DERGARABEDIAN | |||||||||
| NATIONAL DIRECTOR OF DEVELOPMENT | 40.00 | 0.00 | $133,480 | $0 | $37,153 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $1,963,491 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $275,787 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 8 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (4 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd |
|---|---|---|---|---|---|---|---|---|---|
| FAIRCOM NEW YORK INC | |||||||||
| 240 CENTRAL PARK SOUTH | NEW YORK | NY | 10019 | CONSULTANT | $800,764 | ||||
| WSI PAID SEARCH LTD | |||||||||
| TECHNOLOGY | $246,150 | 2343 EGLINTON AVENUE WEST | TORONTO | CA | M6E2L6 | ||||
| JC GEEVER INC | |||||||||
| 11 RIVERSIDE DRIVE | NEW YORK | NY | 10023 | CONSULTANT | $168,534 | ||||
| WALKER STEWART MCKEOUGH | |||||||||
| 240 CENTRAL PARK SOUTH | NEW YORK | NY | 10019 | CONSULTANT | $166,650 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 4 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $5,630,722 | FundraisingAmt |
| All Other Contributions | $14,508,977 | AllOtherContributionsAmt |
| Noncash Contributions | $94,723 | NoncashContributionsAmt |
| Total Contributions | $20,139,699 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,693,066 | TotalRevenueColumnAmt |
| Exclusion | $1,693,066 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $11,255 | TotalRevenueColumnAmt |
| Exclusion | $11,255 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $154,420,696 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $145,530,761 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $8,889,935 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $8,889,935 | TotalRevenueColumnAmt |
| Exclusion | $8,889,935 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $0 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $5,630,722 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $287,450 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$287,450 | TotalRevenueColumnAmt |
| Exclusion | -$287,450 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $30,446,505 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $10,306,806 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $25,269,054 | TotalAmt |
| Program Services | $25,269,054 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $199,953 | TotalAmt |
| Program Services | $199,953 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,221,077 | TotalAmt |
| Program Services | $346,045 | ProgramServicesAmt |
| Management And General | $627,562 | ManagementAndGeneralAmt |
| Fundraising | $247,470 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,792,507 | TotalAmt |
| Program Services | $824,285 | ProgramServicesAmt |
| Management And General | $432,239 | ManagementAndGeneralAmt |
| Fundraising | $535,983 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $115,076 | TotalAmt |
| Program Services | $44,690 | ProgramServicesAmt |
| Management And General | $40,469 | ManagementAndGeneralAmt |
| Fundraising | $29,917 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $318,175 | TotalAmt |
| Program Services | $123,564 | ProgramServicesAmt |
| Management And General | $111,894 | ManagementAndGeneralAmt |
| Fundraising | $82,717 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $629,882 | TotalAmt |
| Program Services | $237,831 | ProgramServicesAmt |
| Management And General | $234,664 | ManagementAndGeneralAmt |
| Fundraising | $157,387 | FundraisingAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $521,137 | TotalAmt |
| Fundraising | $521,137 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $153,022 | TotalAmt |
| Management And General | $153,022 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $654,002 | TotalAmt |
| Program Services | $199,774 | ProgramServicesAmt |
| Management And General | $387,796 | ManagementAndGeneralAmt |
| Fundraising | $66,432 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $692,413 | TotalAmt |
| Fundraising | $692,413 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $458,281 | TotalAmt |
| Program Services | $201,644 | ProgramServicesAmt |
| Management And General | $73,325 | ManagementAndGeneralAmt |
| Fundraising | $183,312 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $255,086 | TotalAmt |
| Program Services | $114,789 | ProgramServicesAmt |
| Management And General | $38,263 | ManagementAndGeneralAmt |
| Fundraising | $102,034 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $40,694 | TotalAmt |
| Program Services | $6,104 | ProgramServicesAmt |
| Management And General | $8,139 | ManagementAndGeneralAmt |
| Fundraising | $26,451 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $88,196 | TotalAmt |
| Program Services | $38,807 | ProgramServicesAmt |
| Management And General | $14,111 | ManagementAndGeneralAmt |
| Fundraising | $35,278 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $45,094 | TotalAmt |
| Program Services | $20,293 | ProgramServicesAmt |
| Management And General | $6,764 | ManagementAndGeneralAmt |
| Fundraising | $18,037 | FundraisingAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| DIRECT MAIL DESIGN & PR | $1,163,972 | $403,160 | $295,223 | $465,589 |
| BANK & CREDIT CARD FEES | $201,066 | $15,079 | $185,987 | |
| RESEARCH SUPPORT | $15,970 | $15,970 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $33,834,657 | TotalAmt |
| Program Services | $28,045,963 | ProgramServicesAmt |
| Management And General | $2,438,550 | ManagementAndGeneralAmt |
| Fundraising | $3,350,144 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,253,446 | BOYAmt |
| EOY | $2,308,831 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $515,050 | BOYAmt |
| EOY | $1,982,801 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,508,338 | BOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | $1,234 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $190,633 | BOYAmt |
| EOY | $211,815 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $388,811 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $193,616 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $131,630 | BOYAmt |
| EOY | $195,195 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $89,962,535 | BOYAmt |
| EOY | $73,805,521 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $96,561,632 | BOYAmt |
| EOY | $78,505,397 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $533,611 | BOYAmt |
| EOY | $760,077 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,997,905 | BOYAmt |
| EOY | $7,629,947 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $82,959 | BOYAmt |
| EOY | $83,740 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,614,475 | BOYAmt |
| EOY | $8,473,764 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $92,560,157 | BOYAmt |
| EOY | $68,371,633 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $387,000 | BOYAmt |
| EOY | $1,660,000 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $92,947,157 | BOYAmt |
| EOY | $70,031,633 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $96,561,632 | BOYAmt |
| EOY | $78,505,397 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$3,388,152 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$19,527,372 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $12,048,978 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $15,969,356 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $13,046,433 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $15,661,608 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $20,139,699 | CurrentTaxYearAmt |
| Total | $76,866,074 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $12,048,978 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $15,969,356 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $13,046,433 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $15,661,608 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $20,139,699 | CurrentTaxYearAmt |
| Total | $76,866,074 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $13,530,515 | SubstantialContributorsTotAmt |
| Public Support Total170 | $63,335,559 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $515,595 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,755,392 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,417,283 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $3,252,026 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,704,321 | CurrentTaxYearAmt |
| Total | $9,644,617 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $99,169 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $371,093 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $219,523 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $8,150 | CurrentTaxYearMinus1YearAmt |
| Total | $697,935 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $87,208,626 | TotalSupportAmt |
| Public Support CY170 | 0.72630 | PublicSupportCY170Pct |
| Public Support PY170 | 0.55270 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE A, PART II | FormAndLineReferenceDesc |
| Explanation | THE FOUNDATION CHANGED ITS FISCAL YEAR END DATE TO JUNE 30TH IN 2018, RESULTING IN A SHORT PERIOD TAX YEAR OF SIX MONTHS FROM JANUARY 1 - JUNE 30, 2018. AS A RESULT, AMOUNTS REPORTED IN COLUMN (A) REFLECT AMOUNTS FOR THE SHORT PERIOD JANUARY 1, 2018 - JUNE 30, 2018. | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,865 | OtherCostOrOtherBasisAmt |
| Depreciation | $5,865 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $18,631 | OtherCostOrOtherBasisAmt |
| Depreciation | $10,398 | DepreciationAmt |
| Book Value | $8,233 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $364,315 | OtherCostOrOtherBasisAmt |
| Depreciation | $177,353 | DepreciationAmt |
| Book Value | $186,962 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $195,195 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | DEFERRED RENT OBLIGATION | Desc |
| Amt | $83,740 | Amt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $83,740 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $10,946,804 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$19,527,372 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $180,693 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | -$19,346,679 | RevenueNotReportedAmt |
| Revenue Subtotal | $30,293,483 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $153,022 | InvestmentExpensesNotIncldAmt |
| Revenue Not Reported Fincl Stmt | $153,022 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $30,446,505 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $33,862,328 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $180,693 | DonatedServicesUseFcltsAmt |
| Expenses Not Reported | $180,693 | ExpensesNotReportedAmt |
| Expenses Subtotal | $33,681,635 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $153,022 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $153,022 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $33,834,657 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART X, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THE FOUNDATION HAS RECEIVED A FINAL DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE STATING THAT THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3). THE FOUNDATION IS TREATED AS A PUBLIC CHARITY AS DEFINED IN SECTIONS 509(A)(1) AND 170(B)(1)(A)(VI). THE FOUNDATION FOLLOWS THE PROVISIONS OF ACCOUNTING STANDARDS CODIFICATION (ASC) SUBTOPIC 740-10, INCOME TAXES - OVERALL (ASC 740-10), RELATING TO UNCERTAINTY IN INCOME TAXES. FOR THE FOUNDATION, ASC 740-10 IS PRIMARILY APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME TAX ATTRIBUTABLE TO CERTAIN OF ITS INVESTMENTS. ASC 740-10 ESTABLISHES A MINIMUM THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION OF THE BENEFITS OF POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, IN FILING TAX RETURNS. IT REQUIRES THE EVALUATION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN, IN THE COURSE OF PREPARING THE FOUNDATION'S INCOME TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS ARE "MORE LIKELY THAN NOT" OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. TAX POSITIONS NOT DEEMED TO MEET THE MORE-LIKELY THAN-NOT THRESHOLD ARE RECORDED AS TAX EXPENSE. FOR THE YEARS ENDED JUNE 30, 2022 AND 2021, THE FOUNDATION HAS NOT IDENTIFIED OR PROVIDED FOR ANY SUCH POSITIONS. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | NORTH AMERICA | RegionTxt |
| Offices | 0 | OfficesCnt |
| Employee | 0 | EmployeeCnt |
| Type Of Activities Conducted | GRANTMAKING | TypeOfActivitiesConductedTxt |
| Specific Services Provided | PANCREATIC CANCER RESEARCH | SpecificServicesProvidedTxt |
| Region Total Expenditures | $199,953 | RegionTotalExpendituresAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $199,953 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $199,953 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | NORTH AMERICA | RegionTxt |
| Purpose Of Grant | PANCREATIC CANCER RESEARCH | PurposeOfGrantTxt |
| Cash Grant | $199,953 | CashGrantAmt |
| Manner Of Cash Disbursement | WIRE/EFT | MannerOfCashDisbursementTxt |
| Non Cash Assistance | $0 | NonCashAssistanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 1 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | GRANT MONITORING PROCESS THE ORGANIZATION REQUIRES ALL GRANTEES TO PROVIDE DETAILED REPORTING ON THEIR RESEARCH. THAT REPORTING INCLUDES ACCOUNTING FOR ALL FUNDS AND SHALL BE ACCOMPANIED BY ELECTRONIC COPIES OF ALL ARTICLES, IRRESPECTIVE OF WHETHER THEY WERE PUBLISHED, PRESENTED OR OTHERWISE DISCLOSED, CONCERNING GRANT RESEARCH WRITTEN BY THE PRINCIPAL INVESTIGATOR. FINAL GRANT ACCOUNTING IS DUE FROM THE SPONSORING INSTITUTION AND THE INSTITUTIONS AGREE TO REFUND ANY PORTION OF THE GRANT FUNDS TO THE FOUNDATION THAT WAS NOT USED FOR THE SPECIFIED PURPOSES DESCRIBED HEREIN AND RETURN TO THE FOUNDATION ANY UNEXPENDED FUNDS WITHIN THIRTY (30) DAYS AFTER THE EXPIRATION OR TERMINATION OF THE GRANT TERM, OR AT THE FOUNDATION'S OPTION, THE FOUNDATION MAY, BY WRITTEN NOTICE, ALLOW THE SPONSORING INSTITUTION TO USE ANY REMAINING GRANT FUNDS IN FURTHERANCE OF GRANT RESEARCH IN PROGRESS AT THE TIME OF SUCH EXPIRATION. THE FOUNDATION SHALL HAVE THE RIGHT TO AUDIT THE USE OF GRANT FUNDS. |
| PART III ACCOUNTING METHOD: |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| In Person Solicitations | Yes (X) | InPersonSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (1) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Gross ReceiptsGrossReceiptsAmt | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|---|
| BUCKLEY EVENTS | ||||||||
| 17 MARBLE AVE 19 | PLEASANTVILLE | NY | 10570 | EVENT CONSULTING | 0 | $1,123,066 | $40,000 | $1,083,066 |
| FAIRCOM NEW YORK | ||||||||
| 12 WEST 27TH ST | NEW YORK | NY | 10001 | DIRECT MAIL & MARKETING | 0 | $1,105,639 | $381,915 | $723,724 |
| JC GREEVER INC | ||||||||
| 11 RIVERSIDE DR 2 EW | NEW YORK | NY | 10023 | DONOR MANAGEMENT | 0 | $845,044 | $99,222 | $745,822 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Gross Receipts | $3,073,749 | TotalGrossReceiptsAmt |
| Total Retained By Contractors | $521,137 | TotalRetainedByContractorsAmt |
| Total Net To Organization | $2,552,612 | TotalNetToOrganizationAmt |
| Licensed States | AL | LicensedStatesCd |
| Licensed States | AR | LicensedStatesCd |
| Licensed States | CA | LicensedStatesCd |
| Licensed States | CO | LicensedStatesCd |
| Licensed States | CT | LicensedStatesCd |
| Licensed States | FL | LicensedStatesCd |
| Licensed States | GA | LicensedStatesCd |
| Licensed States | HI | LicensedStatesCd |
| Licensed States | IL | LicensedStatesCd |
| Licensed States | KS | LicensedStatesCd |
| Licensed States | KY | LicensedStatesCd |
| Licensed States | ME | LicensedStatesCd |
| Licensed States | MD | LicensedStatesCd |
| Licensed States | MA | LicensedStatesCd |
| Licensed States | MI | LicensedStatesCd |
| Licensed States | MN | LicensedStatesCd |
| Licensed States | MO | LicensedStatesCd |
| Licensed States | NV | LicensedStatesCd |
| Licensed States | NH | LicensedStatesCd |
| Licensed States | NJ | LicensedStatesCd |
| Licensed States | NM | LicensedStatesCd |
| Licensed States | NY | LicensedStatesCd |
| Licensed States | NC | LicensedStatesCd |
| Licensed States | OH | LicensedStatesCd |
| Licensed States | OK | LicensedStatesCd |
| Licensed States | OR | LicensedStatesCd |
| Licensed States | PA | LicensedStatesCd |
| Licensed States | SC | LicensedStatesCd |
| Licensed States | TN | LicensedStatesCd |
| Licensed States | UT | LicensedStatesCd |
| Licensed States | VA | LicensedStatesCd |
| Licensed States | WA | LicensedStatesCd |
| Licensed States | WV | LicensedStatesCd |
| Licensed States | WI | LicensedStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | BASH | Event1Nm |
| Gross Receipts Event1 | $1,123,066 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $1,123,066 | CharitableContriEvent1Amt |
| Food And Beverage Event1 | $140,425 | FoodAndBeverageEvent1Amt |
| Entertainment Event1 | $5,740 | EntertainmentEvent1Amt |
| Event2 | LI WALK | Event2Nm |
| Gross Receipts Event2 | $791,486 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $791,486 | CharitableContriEvent2Amt |
| Food And Beverage Event2 | $1,119 | FoodAndBeverageEvent2Amt |
| Other Events Total | 274 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $3,716,170 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $3,716,170 | CharitableContriOtherEventsAmt |
| Oth Direct Expnss Other Events | $140,166 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $5,630,722 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $5,630,722 | CharitableContributionsTotAmt |
| Food And Beverage Total Events | $141,544 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $5,740 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $140,166 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $287,450 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$287,450 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (17 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| STAND UP TP CANCER - ENTERTAINMENT INDUSTRY FOUNDATION | |||||||||
| 10880 WILSHIRE BOULDVARD SUITE 1400 | LOS ANGELES | CA | 90024 | 951644609 | 501(C)(3) | $6,472,317 | $0 | PANCREATIC CANCER RESEARCH | |
| JOHNS HOPKINS UNIVERSITY | |||||||||
| 1650 ORLEANS STREET | BALTIMORE | MD | 21287 | 520595110 | 501(C)(3) | $5,174,114 | $0 | PANCREATIC CANCER RESEARCH | |
| BREAK THROUGH CANCER | |||||||||
| PO BOX 390450 770 MASSACHUSETTS AVE | CAMBRIDGE | MA | 02139 | 851681659 | 501(C)(3) | $5,000,000 | $0 | PANCREATIC CANCER RESEARCH | |
| COLD SPRING HARBOR LABORATORY | |||||||||
| ONE BUNGTOWN ROAD COLD SPRING | NEW YORK | NY | 11724 | 112013303 | 501(C)(3) | $1,658,716 | $0 | PANCREATIC CANCER RESEARCH | HARBOR |
| AMERICAN ASSOCIATION FOR CANCER RESEARCH | |||||||||
| 615 CHESTNUT STREET- 17TH FLOOR | PHILADELPHIA | PA | 191064404 | 236251648 | 501(C)(3) | $1,390,839 | $0 | PANCREATIC CANCER RESEARCH | |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | |||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02139 | 042103594 | 501(C)(3) | $1,317,682 | $0 | PANCREATIC CANCER RESEARCH | |
| DANA FARBER CANCER INSTITUTE | |||||||||
| 450 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042263040 | 501(C)(3) | $1,200,000 | $0 | PANCREATIC CANCER RESEARCH | |
| THE TRUSTEES OF COLUMBIA UNIVERSITY | |||||||||
| 615 W 131ST STREET 4TH FLOOR | NEW YORK | NY | 10027 | 135598093 | 501(C)(3) | $787,439 | $0 | PANCREATIC CANCER RESEARCH | |
| THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | |||||||||
| 10010 NORTH TORREY PINES ROAD | LA JOLLA | CA | 92037 | 952160097 | 501(C)(3) | $530,000 | $0 | PANCREATIC CANCER RESEARCH | |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | |||||||||
| PO BOX 741539 | LOS ANGELES | CA | 90074 | 956006144 | 501(C)(3) | $455,000 | $0 | PANCREATIC CANCER RESEARCH | |
| YALE UNIVERSITY | |||||||||
| PO BOX 1873 | NEW HAVEN | CT | 06508 | 060646973 | 501(C)(3) | $299,640 | $0 | PANCREATIC CANCER RESEARCH | |
| MASSACHUSETTES GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501(C)(3) | $250,000 | $0 | PANCREATIC CANCER RESEARCH | |
| NYU GROSSMAN SCHOOL OF MEDICINE | |||||||||
| PO BOX 415026 | BOSTON | MA | 02241 | 135562308 | 501(C)(3) | $200,000 | $0 | PANCREATIC CANCER RESEARCH | |
| THE TRUSTEE OF THE UNIVERSITY OF PENNSYLVANIA | |||||||||
| 3400 CIVIC CENTER BLVD | PHILADELPHIA | PA | 19104 | 231352685 | 501(C)(3) | $200,000 | $0 | PANCREATIC CANCER RESEARCH | |
| OREGON HEALTH AND SCIENCE | |||||||||
| 2730 SW MOODY AVENUE | PORTLAND | OR | 97201 | 931176109 | GOVT | $198,307 | $0 | PANCREATIC CANCER RESEARCH | |
| THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | |||||||||
| 104 AIRPORT DRIVE SUITE 2200 CAMPUS | CHAPEL HILL | NC | 27599 | 566001393 | 501(C)(3) | $75,000 | $0 | PANCREATIC CANCER RESEARCH | BOX 1350 |
| HENRY FORD HEALTH SYSTEM | |||||||||
| 2799 W GRAND BLVD | DETROIT | MI | 48202 | 381357020 | 501(C)(3) | $60,000 | $0 | PANCREATIC CANCER RESEARCH | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 17 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THE FOUNDATION MAKES GRANTS TO 501(C)(3) PUBLIC CHARITIES CONDUCTING PANCREATIC CANCER RESEARCH. AS PART OF THE REQUIREMENT FOR RECEIVING SUCH GRANTS, THE FOUNDATION REQUIRES PERIODIC UPDATES AND REPORTING ON SCIENTIFIC PROGRESS AND FINANCIAL EXPENDITURES. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (1) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (1) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LINDA TANTAWI | ||||||||||||||
| CEO | $318,738 | $0 | $66,354 | $0 | $0 | $0 | $10,900 | $0 | $41,697 | $0 | $437,689 | $0 | $0 | $0 |
| KERRI KAPLAN | ||||||||||||||
| PRESIDENT | $263,267 | $0 | $67,855 | $0 | $0 | $0 | $0 | $0 | $34,257 | $0 | $365,379 | $0 | $0 | $0 |
| JOHANNA RICHMAN | ||||||||||||||
| CFO | $219,303 | $0 | $37,500 | $0 | $26,923 | $0 | $9,923 | $0 | $32,953 | $0 | $326,602 | $0 | $0 | $0 |
| ANDREW RAKEMAN | ||||||||||||||
| VP RESEARCH | $206,078 | $0 | $43,000 | $0 | $0 | $0 | $7,344 | $0 | $39,051 | $0 | $295,473 | $0 | $0 | $0 |
| CATHERINE WEBER | ||||||||||||||
| VP DEVELOPMENT OPS & CONSITUENT SVCS | $195,698 | $0 | $40,000 | $0 | $0 | $0 | $8,000 | $0 | $27,708 | $0 | $271,406 | $0 | $0 | $0 |
| STEPHANIE ELSEA | ||||||||||||||
| VP MARKETING & COMMUNICATIONS | $170,524 | $0 | $35,000 | $0 | $0 | $0 | $7,000 | $0 | $14,012 | $0 | $226,536 | $0 | $0 | $0 |
| STEPHANIE DERGARABEDIAN | ||||||||||||||
| NATIONAL DIRECTOR OF DEVELOPMENT | $118,972 | $0 | $14,508 | $0 | $0 | $0 | $5,031 | $0 | $32,122 | $0 | $170,633 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINES 4A-B | PART I, LINE 4A: SEVERANCE COMPENSATION JASON RICE, NATIONAL DIRECTOR OF EVENTS, RECEIVED A SEVERANCE PAYMENT OF $15,000 IN CALENDAR YEAR 2021. PART I, LINE 4: SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN LINDA TANTAWI, CEO, PARTICIPATES IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN, AND $3,900 OF DEFERRED COMPENSATION RELATED TO THE PLAN IS REPORTED ON SCHEDULE J, PART II, COLUMN (C). |
| PART I, LINE 7 | NONFIXED PAYMENTS IN 2021, OFFICERS AND EMPLOYEES RECEIVED NONFIXED DISCRETIONARY BONUSES AS REPORTED ON SCHEDULE J, PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 25 | ContributionCnt |
| Noncash Contributions Rpt F990 | $94,723 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | AVG MKT VALUE | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE M, PART I, COLUMN (B) | FormAndLineReferenceDesc |
| Explanation | THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A | RESEARCH PROGRAM $26,550,891 GRANTS $25,469,007 THE FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. TO MOVE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $25 MILLION TO RESEARCH DURING FY2022, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2022 TO $250 MILLION. BECAUSE RESEARCH IS FUNDAMENTAL AND PROGRESS IS PARAMOUNT, THE FOUNDATION HAS SUPPORTED NEARLY 320 PROJECTS WORLDWIDE, WITH PARTNERSHIPS AT MORE THAN 80 ACADEMIC INSTITUTIONS. DURING FY2022, MAJOR LUSTGARTEN-FUNDED RESEARCH MILESTONES AND ACHIEVEMENTS HAVE FOCUSED ON: STRETCHING THE BOUNDARIES OF SCIENCE THROUGH CLINICAL TRIALS: THE FOUNDATION ESTABLISHED THE CLINICAL ACCELERATOR INITIATIVE (CAI) TO SHORTEN THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING CUTTING-EDGE BIOMARKERS. THESE "SMARTER" CLINICAL TRIALS WILL GENERATE LARGE VOLUMES OF DATA THAT SCIENTISTS CAN USE NOW AND, IN THE FUTURE, TO INFORM AND IMPROVE CLINICAL TRIALS AND EXPEDITE NEW TREATMENTS. IN 2022, THE FOUNDATION APPROVED $1.5 MILLION TO FUND ONE CAI CLINICAL TRIAL BASED AT MASSACHUSETTES GENERAL HOSPITAL AND $3.3 MILLION TO SUPPORT THE DEVELOPMENT OF A DEDICATED CLINICAL SCIENCE DATABASE WITH THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. THE TRANSLATIONAL ADVISORY GROUP, LED BY CHIEF MEDICAL ADVISOR DR. ELIZABETH JAFFEE AND COMPRISED OF RENOWNED PANCREATIC CANCER EXPERTS, GUIDES THE CAI BY IDENTIFYING, REVIEWING AND DEVELOPING THE BEST TRANSLATIONAL PROJECTS TO IMPACT PATIENT CARE IN THE CLINIC. THE TRANSLATIONAL ADVISORY GROUP IS BUILDING A NETWORK OF SITES TO EXECUTE THE PROPOSED RESEARCH IN SMALL CLINICAL TRIALS OF 10-20 PATIENTS EACH. THESE SCIENCE-DRIVEN STUDIES COULD DRAMATICALLY INFORM RESEARCH, ENABLING INVESTIGATORS TO QUICKLY DETERMINE IF PATIENTS ARE RESPONDING TO SPECIFIC TREATMENT APPROACHES AND WHY - INFORMATION THAT WILL HELP ENHANCE CLINICAL TRIALS AND ULTIMATELY, CLINICAL CARE. LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE (LABS) PROGRAM: A HALLMARK OF THE LUSTGARTEN FOUNDATION'S UNIQUE RESEARCH STRATEGY, THE LABS PROGRAM PROVIDES LONG-TERM FUNDING TO PROMOTE THE DEVELOPMENT OF INNOVATIVE IDEAS AND SPEED THE PACE OF DISCOVERY BY INCENTIVIZING INTERDISCIPLINARY TEAM SCIENCE. THE LABS PROGRAM IS COMMITTED TO SHARING EXPERTISE ACROSS DIVERSE FIELDS, WITH THE GOAL OF ADVANCING KNOWLEDGE AND REFINING OUR COLLECTIVE UNDERSTANDING OF COMPLEX SYSTEMS AND PATHWAYS. THE SIX LABS PROGRAM SITES ARE: - COLD SPRING HARBOR LABORATORY (LONG ISLAND, NEW YORK) FOCUSING ON PERSONALIZED MEDICINE, DR. DAVID TUVESON LEADS THE LABS SITE AT COLD SPRING HARBOR LABORATORY, DESIGNING NEW MODELS OF THE DISEASE AND DISCOVERING NOVEL THERAPEUTIC AND DIAGNOSTIC PLATFORMS TO BRING NEW OPTIONS TO PATIENTS MORE RAPIDLY. DR. TUVESON WAS THE FIRST SCIENTIST TO DEVELOP A PANCREATIC CANCER ORGANOID - A THREE-DIMENSIONAL CELL CULTURE SYSTEM WHICH REPRODUCES A PATIENT'S TUMOR. THIS ENABLES RESEARCHERS TO REPEATEDLY TEST THE EFFECTIVENESS OF DIFFERENT DRUGS TO ACCURATELY PREDICT HOW A PATIENT WILL RESPOND TO VARIOUS THERAPIES, OFFERING THE HOPE OF PERSONALIZED CANCER TREATMENTS. IN ADDITION TO OTHER PROJECTS, THE LAB'S ORGANOID FACILITY IS GROWING AND TESTING ORGANOIDS FOR THE ONGOING PASS-01 CLINICAL TRIAL. - DANA-FARBER CANCER INSTITUTE (BOSTON, MASSACHUSETTS) LEARNING FROM PATIENTS TO ADVANCE RESEARCH UNDER THE LEADERSHIP OF DR. BRIAN WOLPIN, THE LABS SITE AT DANA-FARBER IS A CRITICAL HUB FOR ADVANCING RESEARCH FROM THE LABORATORY TO THE CLINIC, INITIATING SCIENTIFICALLY-DRIVEN CLINICAL TRIALS AND IDENTIFYING NEW APPROACHES TO EARLY INTERCEPTION/DETECTION. DR. WOLPIN AND HIS TEAM ARE ALSO ANALYZING PANCREATIC CANCER SUBTYPES TO UNDERSTAND MECHANISMS OF DRUG RESISTANCE AND THE GENETIC DRIVERS THAT DETERMINE EACH SUBTYPE. HE IS EVALUATING NEW, PERSONALIZED TREATMENT APPROACHES BASED ON MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF THE PATIENT'S TUMOR. - JOHNS HOPKINS (BALTIMORE, MARYLAND) GUIDED BY GENETICS, FOCUSED ON PANCREATIC CANCER DIRECTED BY DR. BERT VOGELSTEIN, THE LABS SITE AT JOHNS HOPKINS IS USING ITS EXPERTISE IN EARLY DETECTION AND INTERCEPTION OF PANCREATIC CANCER TO DISCOVER PANCREATIC CANCER AT AN EARLIER STAGE, WHEN PATIENTS MAY BE SURGICAL CANDIDATES, AND IS DEVELOPING NEW THERAPEUTIC APPROACHES BASED ON GENETIC ALTERATIONS. IN 2021, EXACT SCIENCES ACQUIRED THE RIGHTS TO CANCERSEEK, A POWERFUL BLOOD TEST CAPABLE OF DETECTING THE EARLY PRESENCE OF MULTIPLE CANCERS AND DEVELOPED THROUGH LUSTGARTEN FUNDING AT THE JOHNS HOPKINS LABS SITE. EXACT SCIENCES IS PREPARING TO INITIATE A 100,000-PERSON REGISTRATION TRIAL AS A STEP TOWARD FDA APPROVAL. (PLEASE SEE EARLY EVENTS OF PANCREATIC CANCER WITHIN THIS DOCUMENT FOR MORE INFORMATION ON EARLY DETECTION ADVANCEMENTS.) - JOHNS HOPKINS (BALTIMORE, MARYLAND) ADVANCING IMMUNOLOGY LED BY DR. ELIZABETH JAFFEE, THE SECOND LABS SITE AT JOHNS HOPKINS IS WORKING TO BRING NOVEL THERAPIES FOR PANCREATIC CANCER TO THE CLINIC AS QUICKLY AS POSSIBLE. BUILDING ON DECADES OF EXPERIENCE AND EXPERTISE IN THE IMMUNOLOGY OF PANCREATIC CANCER, DR. JAFFEE AND HER TEAM ARE FOCUSING ON IMMUNE THERAPIES AND DEVELOPING APPROACHES TO BRING THE BENEFITS OF THIS REVOLUTIONARY APPROACH TO TREATING TUMORS TO PANCREATIC CANCER. - MASSACHUSETTS INSTITUTE OF TECHNOLOGY (CAMBRIDGE, MASSACHUSETTS) USING TECHNOLOGY TO INCREASE PRECISION IN PANCREATIC CANCER RESEARCH THE LABS SITE AT MIT IS LEVERAGING ITS UNPARALLELED EXPERTISE IN CANCER BIOLOGY AND ENGINEERING TO ADVANCE PANCREATIC CANCER RESEARCH. LED BY DR. TYLER JACKS, THE LABORATORY IS STUDYING GENETIC EVENTS CONTRIBUTING TO CANCER DEVELOPMENT AND EXAMINING THE IMMUNE RESPONSES TO THE DISEASE USING MOLECULAR PROFILING TO IDENTIFY TUMOR MUTATIONS. DR. JACKS AND HIS TEAM ALSO ARE RUNNING PRECLINICAL TRIALS IN MOUSE MODEL SYSTEMS TO SEE WHICH DRUGS AND DRUG COMBINATIONS WORK BEST TO BRING ABOUT A PROPER IMMUNE RESPONSE AGAINST PANCREATIC CANCER. - SALK INSTITUTE FOR BIOLOGICAL STUDIES (LA JOLLA, CALIFORNIA) NEW APPROACHES, NEW TARGETS THE LABS (LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE) SITE AT THE SALK INSTITUTE IS LED BY FOUR CO-PRINCIPAL INVESTIGATORS: PROFESSORS REUBEN SHAW, RONALD EVANS, TONY HUNTER, AND DANNIELLE ENGLE. THESE RESEARCHERS AND THEIR TEAMS ARE EXPLORING UNIQUE AND UNDERSTUDIED AREAS RELATED TO DIAGNOSING AND TREATING PANCREATIC CANCER AND ARE FOCUSED ON IDENTIFYING AND VALIDATING NEW TARGETS FOR PANCREATIC CANCER DRUGS AND BIOMARKERS. REUBEN SHAW, PROFESSOR IN THE MOLECULAR AND CELL BIOLOGY LABORATORY AND WILLIAM R. BRODY CHAIR, EXPLORES THE ROLE OF LIPID METABOLISM. RONALD EVANS, PROFESSOR IN THE GENE EXPRESSION LABORATORY AND MARCH OF DIMES CHAIR IN MOLECULAR AND DEVELOPMENT BIOLOGY, INVESTIGATES TRANSCRIPTIONAL AND EPIGENETIC TARGETS. TONY HUNTER, AMERICAN CANCER SOCIETY PROFESSOR IN THE MOLECULAR AND CELL BIOLOGY LABORATORY AND RENATO DULBECCO CHAIR, WILL CONTINUE HIS RENOWNED EXPLORATION OF KINASE DRUG TARGETS. DANNIELLE ENGLE, ASSISTANT PROFESSOR IN THE REGULATORY BIOLOGY LABORATORY, ADDRESSES VULNERABILITIES IN GLYCANS, CARBOHYDRATES THAT COAT PROTEINS AND CELLS. MICHAEL DOWNES, SENIOR STAFF SCIENTIST IN THE GENE EXPRESSION LABORATORY, WILL OVERSEE THE CENTRAL CORE FACILITY STUDYING CHANGES IN PANCREATIC CANCER, AND DEVELOPING NEW MODELS AND THERAPEUTIC APPROACHES. |
| FORM 990, PART III, LINE 4A | UNDERSTANDING THE EARLY EVENTS OF PANCREATIC CANCER: ALISON KLEIN, PHD, JOHNS HOPKINS SCHOOL OF MEDICINE, IS USING UPDATED WAYS OF SEQUENCING GENES TO DETERMINE IF THERE ARE OTHER GENES BESIDES THE ONES ALREADY KNOWN TO INCREASE THE RISK FOR PANCREATIC CANCER IN FAMILIES. THIS IS CRITICAL BECAUSE IN APPROXIMATELY 80% OF FAMILIES WITH INHERITED PANCREATIC CANCER, THE GENE CAUSING THE RISK IS UNKNOWN. DR. KLEIN AIMS TO IDENTIFY GENETIC CAUSES OF FAMILIAL PANCREATIC CANCER; DISCOVER NEW CANDIDATE PANCREATIC CANCER GENES THAT WERE NOT FOUND USING SHORT-READ SEQUENCING; IDENTIFY FAMILIES WITH GENETIC VARIANTS IN KNOWN PANCREATIC CANCER GENES THAT WERE MISSED USING CONVENTIONAL SEQUENCING APPROACHES; CREATE NEW ALGORITHMS TO IDENTIFY THE CAUSE OF INHERITED DISEASE INCLUDING CANCERS; AND DEVELOP EFFECTIVE METHODS FOR LARGE-SCALE, LONG-RANGE GENOMIC SEQUENCING SO DOCTORS CAN MONITOR FOR RISK IN THEIR PATIENTS. LAURA WOOD, MD, PHD, JOHNS HOPKINS UNIVERSITY, DEVELOPED CODA, A THREE-DIMENSIONAL MODELING TECHNIQUE USING SLICES OF TISSUES TO BUILD A MODEL SHOWING WHAT HAPPENS WHEN CELLS TOUCH OTHER CELLS TO DETERMINE IF THAT INTERACTION HAS AN IMPACT ON PANCREATIC CANCER DEVELOPMENT. USING CODA, SHE WILL ANALYZE NORMAL PANCREATIC TISSUE AND EXAMINE THE SPECIFIC CELLULAR AND MOLECULAR CHANGES THAT OCCUR IN OLDER PATIENTS WHO ARE AT AN INCREASED FAMILIAL RISK. DR. WOOD IS ALSO EXAMINING PEOPLE WITH PRECANCEROUS LESIONS CALLED PANINS TO UNDERSTAND WHAT CAUSES A LESION TO CHANGE FROM BENIGN, WHICH REQUIRES MONITORING, TO MALIGNANT, WHICH REQUIRES SURGICAL INTERVENTION. IDENTIFYING NOVEL THERAPEUTIC APPROACHES: THE FOUNDATION'S THERAPEUTICS-FOCUSED RESEARCH PROGRAM WAS CREATED TO ENSURE A ROBUST AND FLOURISHING PIPELINE OF POTENTIAL TREATMENTS AND TO ENABLE COLLABORATION. TO DATE, THE THERAPEUTICS-FOCUSED RESEARCH PROGRAM HAS AWARDED 10 GRANTS TOTALING $11.2 MILLION. FUNDED PROJECTS ADDRESS FOUR KEY AREAS OF PANCREATIC CANCER BIOLOGY: - LEARNING HOW THE STROMA - THE SUPPORTIVE TISSUE SURROUNDING THE PANCREATIC TUMOR - MAY HELP PROTECT TUMORS FROM THE IMMUNE SYSTEM AND RESIST THERAPIES. - UNDERSTANDING AND DISCOVERING HOW TO BLOCK THE INFLAMMATORY SIGNALS THAT CAN LEAD TO PANCREATIC CANCER AND OTHER PANCREATIC DISEASES IN RESPONSE TO ENVIRONMENTAL CAUSES. - DETERMINING WAYS TO STOP TUMOR CELL GROWTH BY BLOCKING THE ABNORMAL METABOLIC PATHWAYS USED BY PANCREATIC CANCER CELLS. - PREVENTING THE SPREAD - OR METASTASIS - OF CANCER BY ISOLATING METASTATIC TRIGGERS IN CANCER CELLS AND THE STROMA. EXPANDING COLLABORATION WITH STAND UP TO CANCER: THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE HAS SUPPORTED RESEARCH LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS INCLUDING NEARLY 30 CLINICAL TRIALS. IN FY22, THE COLLECTIVE FUNDED THE FOLLOWING NEW RESEARCH: AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2022 ANNUAL MEETING, VINOD BALACHANDRAN, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, PRESENTED HIS RESULTS OF THE FIRST TRIAL TESTING A PERSONALIZED MESSENGER RNA (MRNA) VACCINE. THE PHASE 1 TRIAL WAS THE CULMINATION OF YEARS OF RESEARCH LEADING TO THE CRITICAL DISCOVERY THAT LONG-TERM PANCREATIC CANCER SURVIVORS HAVE SPECIFIC IMMUNE RESPONSES THE TEAM HOPED TO MIMIC WITH THE VACCINES. THE ASCO PRESENTATION FOLLOWED THE TEAM'S SECOND PAPER PUBLISHED IN THE SCIENTIFIC JOURNAL NATURE (6/9/22). THE RESULTS SUGGEST THE POSSIBILITY OF DURABLE PROTECTION AGAINST PANCREATIC CANCER IF AN IMMUNE RESPONSE CAN BE DRIVEN AGAINST TUMOR-SPECIFIC TARGETS. THE STUDY ALSO DEMONSTRATES THE FEASIBILITY OF DEVELOPING PATIENT-SPECIFIC, PERSONALIZED VACCINES IN A CLINICALLY RELEVANT TIMEFRAME. ELIZABETH JAFFEE, MD, JOHNS HOPKINS, THE LUSTGARTEN FOUNDATION'S CHIEF MEDICAL ADVISOR, DIRECTS THE FIRST-EVER VACCINE TRIAL AIMED AT PREVENTING PANCREATIC CANCER IN HEALTHY INDIVIDUALS WITH AN ELEVATED RISK FOR THE DISEASE BASED ON THEIR GENETICS OR FAMILY HISTORY OF PANCREATIC CANCER. DR. JAFFEE'S STUDY IS ENROLLING 25 PARTICIPANTS AND WILL MEASURE THE SAFETY AND IMMUNE RESPONSE TO A VACCINE AGAINST MUTANT KRAS PROTEINS, THE MOST COMMON DRIVER OF PANCREATIC CANCER. IF DEEMED SAFE AND EFFECTIVE, THE NEXT STEP IS TO DETERMINE IF IMMUNITY AGAINST THIS MUTATED PROTEIN IS ABLE TO DELAY OR PREVENT PANCREATIC CANCER. ADDRESSING EQUITY, DIVERSITY, AND INCLUSION IN PANCREATIC CANCER RESEARCH: SOLVING THE COMPLEX PROBLEM OF PANCREATIC CANCER REQUIRES DIVERSITY OF THOUGHT, EDUCATION, TRAINING, BACKGROUND AND EXPERIENCE TO MOVE PROGRESS FORWARD. OUR COMMITMENT TO ENSURING EQUITY, DIVERSITY AND INCLUSION - ACROSS LUSTGARTEN-FUNDED RESEARCH AND THE SCIENTISTS WE SUPPORT - IS FOUNDATIONAL TO OUR MISSION TO CURE PANCREATIC CANCER. SUPPORTING DISTINGUISHED EARLY-CAREER SCIENTISTS HELPS ENSURE THEIR CONTINUED COMMITMENT TO STUDYING PANCREATIC CANCER. THE LUSTGARTEN FOUNDATION GRANTED TWO CAREER DEVELOPMENT AWARDS TO INCREASE THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS RECEIVING FUNDING FOR PANCREATIC CANCER RESEARCH. THE AWARDS PROGRAM, IN ITS SECOND YEAR, CONTINUES TO SUPPORT INVESTIGATORS COMMITTED TO INCREASING OUR UNDERSTANDING AND TREATMENT OF THIS DISEASE. THE AWARDS HONOR THE LIVES AND LEGACIES OF TWO TRAILBLAZING AMERICANS LOST TO PANCREATIC CANCER - JUSTICE RUTH BADER GINSBURG AND CONGRESSMAN JOHN ROBERT LEWIS. EACH RECIPIENT IS AWARDED A THREE-YEAR, $300,000 GRANT FOR THEIR PANCREATIC CANCER RESEARCH. - 2022 CAREER DEVELOPMENT AWARD IN HONOR OF RUTH BADER GINSBURG WAS GRANTED TO PINGPING HOU, PHD, AN ASSISTANT PROFESSOR AT RUTGERS UNIVERSITY. DR. HOU IS INVESTIGATING AN IMMUNE CELL POPULATION CALLED TUMOR ASSOCIATED MACROPHAGES (TAMS) THAT HAVE BEEN SHOWN TO CAUSE RESISTANCE IN A THERAPY TARGETING KRAS, A KEY DRIVER OF PANCREATIC CANCER. - 2022 CAREER DEVELOPMENT AWARD IN HONOR OF JOHN ROBERT LEWIS WAS GRANTED TO EDWIN MANUEL, PHD, AN ASSISTANT PROFESSOR AT THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE. DR. MANUEL IS DEVELOPING NEW METHODS TO COMBAT PANCREATIC CANCER THERAPEUTIC RESISTANCE AND ADAPTATION, KEY COMPONENTS LEADING TO DISEASE PROGRESSION. PARTNERING WITH BREAK THROUGH CANCER TO ADVANCE KRAS RESEARCH: COMMITTED TO DEVELOPING A THERAPY TARGETING KRAS, A GENE MUTATED IN 90% OF PANCREATIC CANCER CASES, THE LUSTGARTEN FOUNDATION INVESTED $5 MILLION IN SUPPORT OF A 3-YEAR, $15 MILLION PROJECT WITH BREAK THROUGH CANCER ENTITLED "CONQUERING KRAS IN PANCREATIC CANCER." RESEARCHERS WILL INVESTIGATE PROMISING KRAS-TARGETING THERAPIES TO ACCELERATE THE TRANSLATION OF NEW KRAS INHIBITORS INTO EFFECTIVE DRUGS FOR THIS DISEASE. BREAK THROUGH CANCER CREATED A "TEAM LAB" STRUCTURE TO MAXIMIZE INTERDISCIPLINARY COLLABORATION AMONG RESEARCHERS FROM THE NATION'S TOP FIVE CANCER RESEARCH CENTERS (DANA-FARBER CANCER INSTITUTE, JOHNS HOPKINS, MEMORIAL SLOAN KETTERING CANCER CENTER, KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH AT MIT, AND THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER). THEY WILL WORK TOGETHER TO BOLDLY TACKLE THE BIGGEST CHALLENGES IN CANCER, WITH A FOCUS ON PANCREATIC CANCER, OVARIAN CANCER, AND GLIOBLASTOMA, WHICH ALL FACE POOR PROGNOSES AND SLOW RESEARCH PROGRESS. |
| FORM 990, PART III, LINE 4B | PUBLIC EDUCATION AND INFORMATION PROGRAM $677,642 THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTERS - ANNUAL REPORT - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - RESEARCH MILESTONES UPDATE -TIMELINE OF PANCREATIC CANCER RESEARCH MILESTONES - INCREASED FOCUS ON VIDEO, INCLUDING A VIRTUAL TOUR OF THE LUSTGARTEN LAB AT COLD SPRING HARBOR LABORATORY - PANCREATIC CANCER COLLECTIVE RADIO AND DIGITAL PUBLIC SERVICE ANNOUNCEMENTS FOCUSED ON INCREASING DIVERSITY IN CLINICAL TRIALS. WE ALSO CONTINUE DISTRIBUTING OUR NAVIGATING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON MANAGING A PANCREATIC CANCER DIAGNOSIS AND TREATMENT. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG. |
| FORM 990, PART III, LINE 4C | PROFESSIONAL EDUCATION PROGRAM $817,430 PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. THE FOUNDATION BEGAN PREPARING FOR ITS ROLE AS A LEAD SPONSOR FOR THE AACR SPECIAL MEETING ON PANCREATIC CANCER THAT WAS HELD IN BOSTON, MA IN SEPTEMBER 2022. THE FOUNDATION ALSO STARTED PREPARING FOR ITS ANNUAL SCIENTIFIC MEETING FOR THE SCIENTIFIC ADVISORY BOARD AND SELECT RESEARCHERS IN THE BANBURY CENTER AT COLD SPRING HARBOR LABORATORY THAT WAS HELD IN OCTOBER 2022. THESE MEETINGS HELP FOSTER COLLABORATION AND A BETTER UNDERSTANDING OF GLOBAL DEVELOPMENTS IN PANCREATIC CANCER RESEARCH AND PROGRESS/TRENDS TO HELP SHAPE THE FOUNDATION'S ANNUAL RESEARCH PROGRAM AND LONG-TERM STRATEGIC GOALS. |
| FORM 990, PART VI, SECTION A, LINE 2 | CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP. ANDREW LUSTGARTEN, JAMES L. DOLAN, PHILIP D'AMBROSIO, AND QUENTIN DOLAN - BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 IS REVIEWED BY THE PRESIDENT FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER AND THE PRESIDENT WAS REVIEWED AND APPROVED BY THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS IN 2021. THE REVIEW WAS UNDERTAKEN BY A THIRD-PARTY HUMAN RESOURCES CONSULTANT AND INCLUDED THE USE OF COMPARABILITY DATA WHICH WAS CONTEMPORANEOUSLY DOCUMENTED. |
| FORM 990, PART VI, SECTION C, LINE 19 | AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
Comments